Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

191
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
191
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

229
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
229
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

171
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
171
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

225
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
225
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

234
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
234
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

133
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
133
  1. Home
  3. Population Pharmacokinetics To Support Intravenous And Enteral Methadone Dosing In Children.
  1. Home
  3. Population Pharmacokinetics To Support Intravenous And Enteral Methadone Dosing In Children.

Related Experiment Video

Intravascular Delivery of Biologics to the Rat Kidney
07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

8.1K

Population Pharmacokinetics to Support Intravenous and Enteral Methadone Dosing in Children.

Kevin M Watt1, Elizabeth J Thompson2,3, Lisa Lam4

  • 1University of Utah, Salt Lake City, UT, USA.

Journal of Clinical Pharmacology
|December 31, 2025

View abstract on PubMed

Summary
This summary is machine-generated.

Optimal pediatric methadone dosing is now clearer. This study recommends starting doses of 0.1 mg/kg intravenously or 0.2 mg/kg enterally every 8 hours for pain and withdrawal in children, with titration to effect.

Keywords:
childrendosingmethadoneobesitypharmacokinetics

More Related Videos

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
06:59

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings

Published on: November 9, 2016

31.0K
Microsurgical Skills of Establishing Permanent Jugular Vein Cannulation in Rats for Serial Blood Sampling of Orally Administered Drug
08:28

Microsurgical Skills of Establishing Permanent Jugular Vein Cannulation in Rats for Serial Blood Sampling of Orally Administered Drug

Published on: December 14, 2021

9.9K

Related Experiment Videos

Intravascular Delivery of Biologics to the Rat Kidney
07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

8.1K
A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
06:59

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings

Published on: November 9, 2016

31.0K
Microsurgical Skills of Establishing Permanent Jugular Vein Cannulation in Rats for Serial Blood Sampling of Orally Administered Drug
08:28

Microsurgical Skills of Establishing Permanent Jugular Vein Cannulation in Rats for Serial Blood Sampling of Orally Administered Drug

Published on: December 14, 2021

9.9K

Area of Science:

  • Pediatric pharmacology
  • Clinical pharmacy
  • Pharmacokinetics

Background:

  • Methadone is crucial for managing pain and opiate withdrawal in hospitalized children.
  • Current pediatric dosing guidelines for methadone are not well-established.
  • Understanding methadone pharmacokinetics is essential for safe and effective pediatric use.

Purpose of the Study:

  • To characterize the pharmacokinetics of methadone in pediatric patients.
  • To establish optimal dosing strategies for enteral and intravenous methadone administration in children.
  • To provide evidence-based recommendations for pediatric methadone therapy.

Main Methods:

  • Prospective, multi-center, open-label studies conducted across 23 US children's hospitals.
  • Inclusion of 99 pediatric patients (median age 2.3 years) receiving methadone for pain or withdrawal.
  • Analysis of 263 pharmacokinetic samples using a one-compartment population pharmacokinetic model.

    • Main Results:

    • Established median pharmacokinetic parameters: clearance (0.17 L/h/kg), volume of distribution (4.99 L/kg), and half-life (20.5 h).
    • Dosing simulations indicated that 0.1 mg/kg IV or 0.2 mg/kg enteral every 8 hours achieves therapeutic exposures.
    • Identified significant interindividual variability in methadone pharmacokinetics.

    Conclusions:

    • Recommended starting doses: 0.1 mg/kg IV or 0.2 mg/kg enteral (max 10 mg) every 8 hours for pediatric patients.
    • Emphasized the need for dose titration based on individual patient response due to pharmacokinetic variability.
    • Provides a foundation for improved methadone management in pediatric care settings.